Cargando…
Frequency and causes of antifungal treatment changes in allogeneic haematopoïetic cell transplant recipients with invasive mould infections
BACKGROUND: Antifungal treatment duration and changes for invasive mould infections (IMI) have been poorly described. METHODS: We performed a 10‐year cohort study of adult (≥18‐year‐old) allogeneic haematopoietic cell transplant recipients with proven/probable IMI to describe the duration and change...
Autores principales: | Roth, Romain Samuel, Masouridi‐Levrat, Stavroula, Giannotti, Federica, Mamez, Anne‐Claire, Glambedakis, Emmanouil, Lamoth, Frederic, Bochud, Pierre‐Yves, Erard, Veronique, Emonet, Stephane, Van Delden, Christian, Kaiser, Laurent, Chalandon, Yves, Neofytos, Dionysios |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303791/ https://www.ncbi.nlm.nih.gov/pubmed/34936143 http://dx.doi.org/10.1111/myc.13416 |
Ejemplares similares
-
When and how do we stop antifungal treatment for an invasive mould infection in allogeneic haematopoietic cell transplant recipients?
por: Roth, Romain Samuel, et al.
Publicado: (2022) -
Real-Life Considerations on Antifungal Treatment Combinations for the Management of Invasive Mold Infections after Allogeneic Cell Transplantation
por: Glampedakis, Emmanouil, et al.
Publicado: (2021) -
CMV Infection After Letermovir Primary Prophylaxis Discontinuation in Allogeneic Hematopoietic Cell Transplant Recipients
por: Chavaz, Lara, et al.
Publicado: (2023) -
Invasive Mold Infections in Allogeneic Hematopoietic Cell Transplant Recipients in 2020: Have We Made Enough Progress?
por: Roth, Romain Samuel, et al.
Publicado: (2021) -
Real-world experience of sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for FLT3-ITD AML reveals high rates of toxicity-related treatment interruption
por: Morin, Sarah, et al.
Publicado: (2023)